

# Venessa T Chin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4612399/publications.pdf>

Version: 2024-02-01

31  
papers

8,878  
citations

361413

20  
h-index

454955

30  
g-index

35  
all docs

35  
docs citations

35  
times ranked

13966  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. <i>Immunotherapy</i> , 2022, , .	2.0	4
2	High cyclin <scp>E1</scp> protein, but not gene amplification, is prognostic for basalâ€like breast cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, , .	3.0	2
3	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor-Î² as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100576.	1.7	1
4	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.	1.3	90
5	A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. <i>ELife</i> , 2021, 10, .	6.0	14
6	Precision Oncology in Surgery. <i>Annals of Surgery</i> , 2020, 272, 366-376.	4.2	48
7	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.	6.4	78
8	Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. <i>ELife</i> , 2020, 9, .	6.0	7
9	Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naïve, metastatic lung cancer. <i>Oncogene</i> , 2019, 38, 1661-1675.	5.9	26
10	Chemotherapy and radiotherapy for advanced pancreatic cancer. <i>The Cochrane Library</i> , 2018, 2018, CD011044.	2.8	80
11	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018, 67, 2142-2155.	12.1	100
12	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	32
13	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. <i>Oncogene</i> , 2018, 37, 4518-4533.	5.9	45
14	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. <i>Internal Medicine Journal</i> , 2018, 48, 637-644.	0.8	3
15	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
16	Effective modulation of stromal signaling through ROCK inhibition: Is it all in the timing?. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1333973.	0.7	4
17	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	208
18	Hypermethylation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.	1.3	174

#	ARTICLE	IF	CITATIONS
19	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	27.8	2,700
20	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e17.	3.9	51
21	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	27.8	2,132
22	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPACT) Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2029-2037.	7.0	209
23	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 483-497.	4.4	41
24	The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. <i>Small GTPases</i> , 2015, 6, 123-133.	1.6	37
25	Clinical and pathologic features of familial pancreatic cancer. <i>Cancer</i> , 2014, 120, 3669-3675.	4.1	53
26	Personalising pancreas cancer treatment: When tissue is the issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7849.	3.3	22
27	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , 2013, 5, 78.	8.2	97
28	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.	1.6	142
29	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	27.8	1,741
30	Role of FDG-PET in surgical management of patients with colorectal liver metastases. <i>ANZ Journal of Surgery</i> , 2004, 74, 646-652.	0.7	11
31	Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. <i>The Cochrane Library</i> , 0, , .	2.8	0